Biohaven Ltd. (NYSE:BHVN) Shares Sold by Sigma Planning Corp

Sigma Planning Corp lessened its position in shares of Biohaven Ltd. (NYSE:BHVN) by 4.4% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 8,204 shares of the company’s stock after selling 382 shares during the quarter. Sigma Planning Corp’s holdings in Biohaven were worth $410,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Algert Global LLC boosted its holdings in Biohaven by 5.9% in the 2nd quarter. Algert Global LLC now owns 7,402 shares of the company’s stock worth $257,000 after buying an additional 412 shares during the last quarter. Hsbc Holdings PLC increased its position in shares of Biohaven by 6.1% during the second quarter. Hsbc Holdings PLC now owns 8,291 shares of the company’s stock worth $286,000 after purchasing an additional 480 shares in the last quarter. Canton Hathaway LLC raised its stake in Biohaven by 2.3% in the 2nd quarter. Canton Hathaway LLC now owns 21,850 shares of the company’s stock valued at $758,000 after purchasing an additional 500 shares during the last quarter. Arizona State Retirement System lifted its holdings in Biohaven by 3.7% in the 2nd quarter. Arizona State Retirement System now owns 20,575 shares of the company’s stock valued at $714,000 after purchasing an additional 730 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Biohaven by 4.7% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 17,431 shares of the company’s stock worth $605,000 after purchasing an additional 778 shares during the last quarter. Hedge funds and other institutional investors own 88.78% of the company’s stock.

Analysts Set New Price Targets

BHVN has been the subject of a number of recent research reports. Jefferies Financial Group assumed coverage on shares of Biohaven in a research report on Monday, September 16th. They issued a “buy” rating and a $57.00 target price for the company. Royal Bank of Canada lowered their target price on Biohaven from $68.00 to $66.00 and set an “outperform” rating on the stock in a report on Wednesday. Piper Sandler increased their price target on Biohaven from $66.00 to $76.00 and gave the company an “overweight” rating in a report on Monday, September 23rd. William Blair upgraded Biohaven to a “strong-buy” rating in a research report on Friday, August 30th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Biohaven in a report on Wednesday, October 23rd. Thirteen analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $63.42.

Insiders Place Their Bets

In other Biohaven news, Director Gregory Bailey bought 5,000 shares of Biohaven stock in a transaction on Tuesday, September 24th. The shares were bought at an average cost of $44.19 per share, for a total transaction of $220,950.00. Following the acquisition, the director now directly owns 1,620,071 shares in the company, valued at $71,590,937.49. This represents a 0.31 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director John W. Childs purchased 21,052 shares of the company’s stock in a transaction on Wednesday, October 2nd. The stock was acquired at an average price of $47.50 per share, with a total value of $999,970.00. Following the purchase, the director now owns 21,052 shares of the company’s stock, valued at approximately $999,970. This represents a ? increase in their ownership of the stock. The disclosure for this purchase can be found here. 16.00% of the stock is owned by insiders.

Biohaven Trading Down 8.8 %

Shares of BHVN opened at $44.37 on Friday. The company’s 50-day moving average price is $48.16 and its 200 day moving average price is $40.91. Biohaven Ltd. has a 12-month low of $26.80 and a 12-month high of $62.21. The firm has a market cap of $4.49 billion, a P/E ratio of -4.75 and a beta of 1.31.

Biohaven (NYSE:BHVN) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($1.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.67) by ($0.03). Equities research analysts forecast that Biohaven Ltd. will post -8.81 earnings per share for the current year.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.